# 23andMe Holding Co. (ME)

Source: https://www.quantisnow.com/company/ME
Generated: 2026-11-08T09:34:25.508Z

- Ticker: ME
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: 23andme.com

## About

23andMe Holding Co. operates as a consumer genetics and research company. The company provides a crowdsourced platform for genetic research. Its platform has generated various publications on the genetic underpinnings of a range of diseases, conditions, and traits, as well as enables it in pursuing drug discovery programs rooted in human genetics across various disease areas, including oncology, respiratory, and cardiovascular diseases, as well as other therapeutic areas. The company was founded in 2006 and is based in Sunnyvale, California.

## Latest ME news and filings

- 2025-03-28 20:09 UTC [SEC Form 8-K] [SEC Form 8-K filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-23andme-holding-co-5964806)
- 2025-03-26 22:57 UTC [23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law](https://www.quantisnow.com/insight/23andme-confirms-all-potential-buyers-must-agree-to-comply-with-5961814)
- 2025-03-26 20:38 UTC [SEC Form 3] [SEC Form 3 filed by new insider Kvarda Matthew](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-kvarda-matthew-5961400)
- 2025-03-26 20:35 UTC [SEC Form 3] [SEC Form 3 filed by new insider Walper Thomas B.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-walper-thomas-b-5961380)
- 2025-03-24 10:23 UTC [SEC Form 8-K] [23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/23andme-holding-co-filed-sec-form-8-k-regulation-fd-disclosure-5956803)
- 2025-03-24 03:08 UTC [23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process](https://www.quantisnow.com/insight/23andme-initiates-voluntary-chapter-11-process-to-maximize-stakeholder-value-5956709)
- 2025-03-21 11:30 UTC [23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test](https://www.quantisnow.com/insight/23andme-launches-new-homocysteine-mthfr-related-genetic-report-and-accompanying-lab-5955339)
- 2025-03-03 21:35 UTC [23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki](https://www.quantisnow.com/insight/23andme-special-committee-rejects-acquisition-proposal-from-ceo-anne-wojcicki-5920610)
- 2025-02-21 22:05 UTC [SEC Form 4] [Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-actng-ofcr-selsavage-joseph-anthony-covered-exercisetax-liability-5903439)
- 2025-02-06 21:27 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-23andme-holding-co-5875865)
- 2025-01-31 12:30 UTC [23andMe Launches New Genetic Report on Osteoporosis](https://www.quantisnow.com/insight/23andme-launches-new-genetic-report-on-osteoporosis-5864541)
- 2025-01-28 22:25 UTC [23andMe Special Committee Announces Exploration of Strategic Alternatives](https://www.quantisnow.com/insight/23andme-special-committee-announces-exploration-of-strategic-alternatives-5860382)
- 2025-01-28 22:18 UTC [SEC Form 8-K] [23andMe Holding Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/23andme-holding-co-filed-sec-form-8-k-results-of-operations-5860358)
- 2025-01-08 12:30 UTC [Conference Announcement] [23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology](https://www.quantisnow.com/insight/23andme-launches-discover23-to-help-accelerate-large-scale-genetics-research-for-5838737)
- 2024-11-21 21:43 UTC [SEC Form 4] [Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,279 shares, decreasing direct ownership by 5% to 102,122 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-actng-ofcr-selsavage-joseph-anthony-covered-exercisetax-liability-5787075)
- 2024-11-20 12:30 UTC [Conference Announcement] [23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation](https://www.quantisnow.com/insight/23andme-and-mirador-therapeutics-enter-into-strategic-research-collaboration-to-5784240)
- 2024-11-15 21:48 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-23andme-holding-co-5779239)
- 2024-11-15 21:20 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-23andme-holding-co-5778976)
- 2024-11-15 21:03 UTC [SEC Form 144] [SEC Form 144 filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/sec-form-144-filed-by-23andme-holding-co-5778702)
- 2024-11-13 11:00 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-23andme-holding-co-5769654)
- 2024-11-12 17:14 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-23andme-holding-co-5766421)
- 2024-11-12 12:41 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-23andme-holding-co-5765332)
- 2024-11-12 12:30 UTC [Earnings Date] [23andMe Reports Second Quarter Fiscal Year 2025 Financial Results](https://www.quantisnow.com/insight/23andme-reports-second-quarter-fiscal-year-2025-financial-results-5764574)
- 2024-11-11 22:30 UTC [23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future](https://www.quantisnow.com/insight/23andme-announces-business-restructuring-to-streamline-operations-reduce-costs-and-5764289)
- 2024-11-07 22:54 UTC [Earnings Date] [CORRECTION - 23andMe to Report Q2 FY2025 Financial Results](https://www.quantisnow.com/insight/correction---23andme-to-report-q2-fy2025-financial-results-5760424)
- 2024-11-07 12:30 UTC [Earnings Date] [23andMe to Report Q2 FY2025 Financial Results](https://www.quantisnow.com/insight/23andme-to-report-q2-fy2025-financial-results-5757575)
- 2024-11-04 15:59 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-23andme-holding-co-5749831)
- 2024-10-31 20:48 UTC [SEC Form 3] [SEC Form 3 filed by new insider Fernandez Andre J](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-fernandez-andre-j-5746899)
- 2024-10-31 20:47 UTC [SEC Form 3] [SEC Form 3 filed by new insider Frankola Jim](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-frankola-jim-5746895)
- 2024-10-31 20:47 UTC [SEC Form 3] [SEC Form 3 filed by new insider Jensen Mark Edwin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-jensen-mark-edwin-5746893)
- 2024-10-30 21:05 UTC [SEC Form 8-K] [23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/23andme-holding-co-filed-sec-form-8-k-regulation-fd-disclosure-5744529)
- 2024-10-30 21:00 UTC [23andMe Regains Compliance With Nasdaq Listing Requirements](https://www.quantisnow.com/insight/23andme-regains-compliance-with-nasdaq-listing-requirements-5744487)
- 2024-10-29 20:27 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-23andme-holding-co-5741970)
- 2024-10-29 20:06 UTC [SEC Form 8-K] [23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/23andme-holding-co-filed-sec-form-8-k-regulation-fd-disclosure-5741700)
- 2024-10-29 11:30 UTC [Leadership Update] [23andMe Appoints Three New Independent Directors to Board](https://www.quantisnow.com/insight/23andme-appoints-three-new-independent-directors-to-board-5740877)
- 2024-10-21 22:44 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-23andme-holding-co-5732270)
- 2024-10-16 12:21 UTC [SEC Form 8-K] [23andMe Holding Co. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure](https://www.quantisnow.com/insight/23andme-holding-co-filed-sec-form-8-k-material-modification-to-5726733)
- 2024-10-16 12:15 UTC [23andMe Announces Completion of 1-for-20 Reverse Stock Split](https://www.quantisnow.com/insight/23andme-announces-completion-of-1-for-20-reverse-stock-split-5726725)
- 2024-10-11 12:15 UTC [23andMe Announces 1-for-20 Reverse Stock Split](https://www.quantisnow.com/insight/23andme-announces-1-for-20-reverse-stock-split-5723072)
- 2024-09-30 20:58 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-23andme-holding-co-5708786)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ME
- Earnings history: https://www.quantisnow.com/earnings/ME
- Dividend history: https://www.quantisnow.com/dividends/ME
- Insider transactions: https://www.quantisnow.com/insiders/ME
- Options chain: https://www.quantisnow.com/options/ME
- SEC 8-K filings only: https://www.quantisnow.com/company/ME/8-k
- RSS and alerts for ME: https://www.quantisnow.com/docs/rss-feeds.md